Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CGAS-mediated IFN-I signaling contributes to disease progression in drug-refractory epilepsy

ABSTRACT: Epilepsy is a prevalent neurological disease with a third of patients becoming non-responsive to antiepileptic drugs and developing drug-refractory epilepsy (DRE). Here we report that DRE disease progression is contributed by overactive cyclic GMP-AMP synthase (cGAS), a double-stranded DNA sensor that induces type I interferon (IFN-I) signaling. In human DRE microglia, we observe a robust IFN-I signature and the activation of upstream cGAS-STING signaling. Further, in mouse models of Dravet syndrome, a genetic form of DRE, we observe the activation of the cGAS pathway. We show that microglial cGAS can be activated by DNA released from hyperexcitable neurons. Genetic reduction and pharmacological inhibition of cGAS reduces epileptic phenotypes, glial inflammatory signatures, and neuronal transcriptomic changes, underscoring the therapeutic potential of targeting cGAS for DRE treatment.

ORGANISM(S): Mus musculus

PROVIDER: GSE334405 | GEO | 2026/06/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Characterization of 5-hmC DNA Methylation Patterns in the Hippocampus of an Experimental Model of Epilepsy

Project description:Temporal lobe epilepsy is one of the most common refractory epilepsies in the world. Epilepsy progression is controlled through the expression of epilepsy permissive genes, ultimately resulting in a hyperexcitable network and spontaneous seizures. DNA methylation has been explored as a potential epigenetic regulatory mechanism of gene expression in epilepsy, however, the role of 5-hydroxymethylcytosine (5-hmC) has been underexplored to date. 5-hmC is a stable epigenetic mark most abundantly expressed in the brain. In this study, we show that 5-hmC but not 5-methylcytosine (5-mC) is lost in temporal lobe epilepsy. Using 5-hmC meDIP-sequencing, we characterized epileptic 5-hmC distribution in the rat kainic acid model of temporal lobe epilepsy. We identified the correlation of 5-hmC loss and gain with epilepsy-associated gene ontology pathways and implicate the potential involvement of multiple cell types with 5-hmC regulation of temporal lobe epilepsy. Overall, we show that 5-hmC has the potential to be a crucial regulator of epilepsy and epileptic gene expression and are the first to characterize the genomic distribution of 5-hmC in a model of epilepsy.

2025-04-14 | GSE198737 | GEO

Proteomic analysis of cerebrospinal fluid in epileptic and healthy dogs

Project description:This study included four dog groups (group A: 10 healthy dogs, group B: 9 dogs with idiopathic epilepsy receiving antiepileptic medication-AEM, group C: 8 dogs with idiopathic epilepsy without AEM administration and group D: 7 dogs with seizures due to structural brain abnormalities). The epileptic dogs were allocated into these 3 groups after a diagnostic investigation that included laboratory testing, thoracic radiographic and abdominal ultrasonographic examination, brain imaging, CSF routine and proteomic analysis. The purpose of the current study was to investigate and compare the proteomic profile among the four groups of dogs.

2020-10-19 | PXD018893 | Pride

Hippocampal epitranscriptomic (m6A) in human model of Temporal Lobe Epilepsy

Project description:Analogous to DNA methylation and protein phosphorylation it is now well understood that RNA is also subject to extensive processing and modification. N6-methyladenosine (m6A) is the most abundant internal RNA modification and regulates RNA fate in several ways including stability and translational efficiency. The role of m6A in both experimental and human epilepsy remains unknown. Here we use transcriptome-wide m6A arrays to obtain a detailed analysis of the hippocampal m6A-ome from human temporal lobe epilepsy samples. We show that epileptic tissue displays disrupted metabolic and autophagic pathways which may be directly linked to m6A-processing. Together our findings indicate that m6A represents a novel layer of gene regulation complexity in epilepsy and may contribute to the pathomechanisms which drive the development and maintenance of hyperexcitable brain networks.

2025-05-20 | GSE297566 | GEO

Single Cell Transcriptomics of Refractory Epilepsy (RE) patients in Colombia.

Project description:The human neocortex is composed of dozens to hundreds of distinct cell types, whose gene expression patterns maintain the balanced electric signaling during all the life. Although the brain has shown a high adaptive capacity to tolerate disruptions, some alterations in these genetic programs can contribute to the pathogenesis of various neurological disorders, including epilepsy, autism spectrum disorder, Alzheimer’s disease, and Parkinson’s disease. Genetic factors are especially implicated in a specific form known as refractory or drug-resistant epilepsy (DRE), which is diagnosed when two or more antiepileptic treatment regimens fail to control seizures. In this study, we investigated the cellular and molecular landscape of DRE using brain tissue from five pediatric Colombian patients. Six samples collected during surgical resection were analyzed using single-cell RNA sequencing (scRNA-seq) and long-read genome sequencing (PacBio HiFi). We identified differentially expressed genes (DEGs) across distinct cell types, integrating transcriptomic data with single nucleotide polymorphisms (SNPs), insertions, deletions, and structural variants. Functional enrichment analysis revealed glial-driven dysregulation of synaptic signaling, impaired glial–neuronal communication, and altered expression of transporters and calcium signaling genes. Notably, aberrant activation of taste receptors in neurons was associated with neuroinflammatory processes. These findings suggest that DRE arises from complex, cell-type-specific disruptions that compromise network stability and seizure control.

2025-08-04 | GSE302285 | GEO

Hippocampus RNA-sequencing of long-term treatment with Q808

Project description:Antiepileptic drugs (AEDs) are the mainstay treatment in epilepsy and epilepsy treatment usually requires many years and can be lifelong. Thus, evaluating the long-term effect of AEDs is important. Q808 is an innovative antiepileptic chemical under research and development. It exerts effective antiepileptic effect against various epilepsy models. Exploring the gene transcriptomic profile of long-term treatment of Q808 is necessary. In the present study, hippocampus RNA-sequencing was performed to reveal the transcriptome profile of rats after treatment of gavage of Q808 for 28 day.

2022-05-08 | GSE202301 | GEO

Peripheral blood expression profiles of patients with epilepsy receiving and not receiving antiepileptic drug monotherapy and their differential response to the treatment.

Project description:The aim here was to identify mRNA expression biomarkers associated with the disease epilepsy and the antiepileptic drug response. Gene expression profiles of drug-naïve patients with epilepsy were compared with that of healthy controls. The profiles were significantly different between the two groups as well as patients with different epilepsy types i.e. idiopathic, symptomatic and cryptogenic. Besides, patients showing differential response to antiepileptic monotherapies were also having differential blood gene expression profiles.

2020-01-08 | GSE143272 | GEO

Quantitative proteomics of serum samples using tandem mass tags in dogs with recurrent epileptic seizures

Project description:This study included four groups of dogs (group A: healthy controls, group B: idiopathic epilepsy receiving antiepileptic medication (AEM), group C: idiopathic epilepsy without AEM administration, group D: structural epilepsy), for which comparative proteomic analysis of serum samples was performed.

2023-10-30 | PXD041129 | Pride

mtDNA leakage promotes neuron-glia crosstalk to induce epilepsy by cGAS-STING-driven neuroinflammation and serine metabolic reprogramming

Project description:Epilepsy is increasingly recognized as a disorder involving metabolic dysregulation beyond neural hyperexcitability, yet the underlying metabolic mechanisms remain poorly defined. Here, we identify a mitochondrion-immunity-metabolism axis that drives spontaneous chronic epilepsy. Brain-specific deletion of Mic19 impairs mitochondrial cristae structure and mitochondrial integrity in neurons, leading to activation of the Z-mtDNA–ZBP1–RIPK3-MLKL axis and p-MLKL-mediated pore formation on the mitochondrial membrane. This process results in cytosolic and extracellular leakage of mitochondrial DNA (mtDNA), which is subsequently taken up by microglia and triggers cGAS-STING-dependent inflammatory signaling. The resulting neuroinflammation promotes sustained activation of astrocytes. Critically, reactive astrocytes undergo profound metabolic reprogramming, marked by upregulated glycolysis and enhanced L-serine biosynthesis. Astrocyte-derived L-serine is subsequently transferred to neurons and converted into D-serine, a key NMDA receptor co-agonist that enhances neuronal excitability. This metabolic shift in astrocytes exacerbates excitotoxicity and sustains epileptic activity. Importantly, pharmacologic inhibition of STING with H-151 treatment markedly suppresses seizures, reinforcing the therapeutic potential of targeting immunometabolic crosstalk in epilepsy. Our findings reveal that mtDNA-mediated cGAS-STING activation and D-serine act as important drivers of epilepsy initiation, offering new mechanistic insights into neuron-microglia-astrocyte crosstalk and highlighting immunometabolic modulation as a promising therapeutic strategy for epilepsy.

2026-02-11 | GSE319015 | GEO

Drug screening for Dravet syndrome using Scn1a zebrafish mutants

Project description:Severe myoclonic epilepsy of infancy (SMEI), or Dravet syndrome (DS), is a catastrophic pediatric epilepsy with severe intellectual disability, impaired social development, and persistent drug-resistant seizures. One of its primary monogenic causes is a mutation in SCN1A (Nav1.1), a type I voltage-gated sodium channel. In mice, Nav1.1 mutation is associated with reduced sodium current, altered interneuron firing, cognitive deficits, autistic-like traits and seizures. Here we describe a larval zebrafish Nav1.1 mutant that recapitulates salient features of the human SCN1A mutation phenotype. Between three and seven days post-fertilization, Nav1.1 mutants exhibit spontaneous abnormal electrographic activity, hyperactivity and convulsive behaviors. Transcriptomic analysis of Nav1.1 mutants was remarkable for the relatively small fraction of genes that were differentially expressed (~2%) and the lack of compensatory changes in expression for other SCN subunits. Pharmacological studies confirmed an antiepileptic action for the ketogenic diet, benzodiazepine, valproate, potassium bromide and stiripentol in Nav1.1 mutants; acetazolamide, phenytoin, ethosuximide had no effect, carbamazepine and vigabatrin made seizures worse. Using this mutant, we screened a chemical library of 320 compounds and identified four compounds that reduced spontaneous seizure-like behavior and one compound (clemizole) that inhibited convulsive behavior and electrographic seizures. Drug-resistant scn1a zebrafish mutants described here represent a new direction in modeling pediatric epilepsy and could be used to identify novel lead compounds for DS patients 4 Control sibling samples (sample= 10 pooled larvae) and 4 Nav1.1 mutants (sample= 10 pooled larvae) were collected at 6 dpf (days post fertilization). The Nav1.1 mutants were selected based on phenotype (dark color).

2014-01-04 | E-GEOD-43312 | biostudies-arrayexpress

Rat MeDIP Array, naïve, epileptic, and adenosine treated

Project description:Epilepsy causes altered gene expression; transient adenosine treatment inhibits progression of epileptogenesis Hippocampus of epileptic rat is hypermethylated compared to naïve; adenosine treatment causes hypomethylation Metylation state in epileptic rats (9 weeks post kainic acid induced status epilepticus) was compared to naïve (untreated) rats and epileptic rats treated with adenosine for 5 days

2013-09-05 | E-GEOD-45932 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data